Kivu Bioscience Raises $92 Million Series A Led by Novo Holdings to Advance Next-Generation Antibody-Drug Conjugates
October 28, 2024 08:00 AM Eastern Daylight Time SAN FRANCISCO–(BUSINESS WIRE)–Kivu Bioscience, a biotech company developing next-generation antibody-drug conjugates to deliver best-in-class therapeutics, announced today the close of a $92 million Series A financing round…